Canada’s Drug Agency | Drugs, Health Technologies and Systems.

zilucoplan

Details

Key Milestones2
Call for patient/clinician input open12-Jan-24
Call for patient/clinician input closed11-Mar-24
Clarification:

- Patient input submission received from Muscular Dystrophy Canada

Submission received29-Feb-24
Submission accepted14-Mar-24
Review initiated18-Mar-24
Clarification:

- Submission temporarily suspended

Draft CADTH review report(s) provided to sponsor for comment11-Oct-24
Clarification:

- Additional information has been received and the temporary suspension of the review has been lifted

Deadline for sponsors comments23-Oct-24
CDA-AMC review report(s) and responses to comments provided to sponsor15-Nov-24
Expert committee meeting (initial)27-Nov-24
Draft recommendation issued to sponsor10-Dec-24
Draft recommendation posted for stakeholder feedback19-Dec-24
End of feedback period10-Jan-25
Final recommendation issued to sponsor and drug plans23-Jan-25
Final recommendation posted11-Feb-25
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)07-Feb-25
CDA-AMC review report(s) posted-
Last Updated : April 14, 2025

remdesivir

Details

Key Milestones2
Call for patient/clinician input open08-Jan-24
Call for patient/clinician input closed04-Mar-24
Clarification:

- Patient input submission received from the Gastrointestinal Society

Submission received01-Mar-24
Submission accepted18-Mar-24
Review initiated19-Mar-24
Draft Canada's Drug Agency review report(s) provided to sponsor for comment13-May-24
Deadline for sponsors comments23-May-24
Canada's Drug Agency review report(s) and responses to comments provided to sponsor14-Jun-24
Expert committee meeting (initial)26-Jun-24
Draft recommendation issued to sponsor09-Jul-24
Draft recommendation posted for stakeholder feedback18-Jul-24
End of feedback period01-Aug-24
Final recommendation issued to sponsor and drug plans16-Aug-24
Final recommendation posted04-Sep-24
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)30-Aug-24
Canada's Drug Agency review report(s) posted26-Nov-24
Last Updated : November 26, 2024

remdesivir

Details

Key Milestones2
Call for patient/clinician input openJanuary 08, 2024
Call for patient/clinician input closedMarch 04, 2024
Clarification:

- No patient input submission received

Submission receivedMarch 01, 2024
Submission acceptedMarch 18, 2024
Review initiatedMarch 19, 2024
Draft CADTH review report(s) provided to sponsor for commentMay 13, 2024
Deadline for sponsors commentsMay 23, 2024
CADTH review report(s) and responses to comments provided to sponsorJune 14, 2024
Expert committee meeting (initial)June 26, 2024
Draft recommendation issued to sponsorJuly 09, 2024
Draft recommendation posted for stakeholder feedbackJuly 18, 2024
End of feedback periodAugust 01, 2024
Final recommendation issued to sponsor and drug plansAugust 16, 2024
Final recommendation postedSeptember 04, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)August 30, 2024
CADTH review report(s) postedJanuary 08, 2025
Last Updated : January 8, 2025

capivasertib

Details

Key Milestones2
Call for patient/clinician input openJanuary 03, 2024
Call for patient/clinician input closedFebruary 26, 2024
Clarification:

- Patient input submission received from Breast Cancer Canada, Canadian Breast Cancer Network and Rethink Breast Cancer

Submission receivedFebruary 14, 2024
Submission acceptedFebruary 29, 2024
Review initiatedMarch 01, 2024
Draft CADTH review report(s) provided to sponsor for commentMay 27, 2024
Deadline for sponsors commentsJune 05, 2024
CADTH review report(s) and responses to comments provided to sponsorJune 27, 2024
Expert committee meeting (initial)July 10, 2024
Draft recommendation issued to sponsorJuly 23, 2024
Draft recommendation posted for stakeholder feedbackAugust 01, 2024
End of feedback periodAugust 16, 2024
Final recommendation issued to sponsor and drug plansAugust 30, 2024
Final recommendation postedSeptember 18, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)September 16, 2024
CADTH review report(s) postedJanuary 06, 2025
Last Updated : January 29, 2025

Nab-paclitaxel

Details

Key Milestones2
Call for patient/clinician input openJanuary 02, 2024
Call for patient/clinician input closedFebruary 26, 2024
Call for industry input openJanuary 02, 2024
Call for industry input closedFebruary 26, 2024
Submission receivedDecember 21, 2023
Expert committee meeting (initial)July 04, 2024
Draft recommendation posted for stakeholder feedbackAugust 01, 2024
End of feedback periodAugust 16, 2024
Final recommendation postedSeptember 24, 2024
Canada's Drug Agency review report(s) postedAugust 19, 2024
Last Updated : October 30, 2024

Mepolizumab

Details

Key Milestones2
Submission received19-Dec-23
Review initiated20-Dec-23
Expert committee meeting (initial)04-Jul-24
Draft recommendation posted for stakeholder feedback01-Aug-24
End of feedback period16-Aug-24
Clarification:

- Reconsideration: minor revisions requested by drug programs

- Request for reconsideration accepted

Final recommendation posted25-Nov-24
CADTH review report(s) posted10-Sep-24
Last Updated : February 10, 2025

cabotegravir

Details

Key Milestones2
Call for patient/clinician input openDecember 14, 2023
Call for patient/clinician input closedFebruary 12, 2024
Clarification:

- Patient input submission received from Peer Outreach Support Services & Education (POSSE), Africans in Partnership Against AIDS, Community-Based Research Centre, CATIE and HIV Network of Edmonton Society

Submission receivedFebruary 01, 2024
Submission acceptedFebruary 15, 2024
Review initiatedFebruary 16, 2024
Draft CADTH review report(s) provided to sponsor for commentMay 07, 2024
Deadline for sponsors commentsMay 16, 2024
CADTH review report(s) and responses to comments provided to sponsorJune 14, 2024
Expert committee meeting (initial)June 26, 2024
Draft recommendation issued to sponsorJuly 09, 2024
Draft recommendation posted for stakeholder feedbackJuly 18, 2024
End of feedback periodAugust 01, 2024
Final recommendation issued to sponsor and drug plansAugust 14, 2024
Final recommendation postedAugust 30, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)August 28, 2024
CADTH review report(s) postedJanuary 14, 2025
Last Updated : January 14, 2025

everolimus

Details

Key Milestones2
Call for patient/clinician input open14-Dec-23
Call for patient input open14-Dec-23
Call for patient input closed12-Feb-24
Call for patient/clinician input closed12-Feb-24
Call for industry input open14-Dec-23
Call for industry input closed12-Feb-24
Submission received12-Dec-23
Review initiated13-Dec-23
Expert committee meeting (initial)19-Sep-24
Draft recommendation posted for stakeholder feedback17-Oct-24
End of feedback period31-Oct-24
Final recommendation posted03-Dec-24
CADTH review report(s) posted07-Nov-24
Last Updated : February 10, 2025

pegcetacoplan

Details

Key Milestones2
Call for patient/clinician input open23-May-24
Clarification:

- CDA-AMC initially posted the call for patient from Dec 13 to Feb 12 . The pending submission was subsequently delayed and CDA-AMC re-posted the call for patient input when the revised filing date was received.

Call for patient/clinician input closed12-Jul-24
Clarification:

- Patient input submission received from Fighting Blindness Canada, The Canadian Council of the Blind, CNIB, International Federation on Ageing, Vision Loss Rehabilitation Canada, Association Québécoise de la dégénérescence maculaire

Submission received23-Jul-24
Submission accepted07-Aug-24
Review initiated08-Aug-24
Draft CADTH review report(s) provided to sponsor for comment01-Nov-24
Deadline for sponsors comments13-Nov-24
Clarification:

- Voluntarily withdrawn by the sponsor on 04 Feb 2025

Last Updated : March 11, 2025

etrasimod

Details

Key Milestones2
Call for patient/clinician input openDecember 08, 2023
Call for patient/clinician input closedFebruary 12, 2024
Clarification:

- Patient input submission received from Crohn's and Colitis Canada and Gastrointestinal Society

Submission receivedFebruary 05, 2024
Submission acceptedFebruary 20, 2024
Review initiatedFebruary 21, 2024
Draft CADTH review report(s) provided to sponsor for commentMay 14, 2024
Deadline for sponsors commentsMay 24, 2024
CADTH review report(s) and responses to comments provided to sponsorJune 14, 2024
Expert committee meeting (initial)June 26, 2024
Draft recommendation issued to sponsorJuly 10, 2024
Draft recommendation posted for stakeholder feedbackJuly 18, 2024
End of feedback periodAugust 01, 2024
Final recommendation issued to sponsor and drug plansAugust 14, 2024
Final recommendation postedAugust 30, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)August 28, 2024
CADTH review report(s) postedDecember 04, 2024
Last Updated : December 9, 2024